October 31, 2009

Treatment of Anemia in Chronic Kidney Disease — Strategies Based on Evidence

This editorial provides insight into the interpretation of the TREAT study, “A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease”.

Related Articles:

Anemia, Chronic Kidney Disease
  • Gary G Kardos, MD

    An interesting study and points out once again how complicated and interwoven are the multiple aspects of CKD before and on RRT. Although there may a variety of confounders, the duration of CKD prior to RRT and associated CV Disease, Hypertension, Hyperlipidemia, DM, Renaal Osteodystrophy etc. are undoubtedly accounting for the majority of deaths during this study. Far more complete, longer, and more carefully designed studies will be required to explore this true value of Darbepoitin and other such drugs and control of CKD associated anemia.